Should I discontinue aspirin before undergoing a thoracentesis?

No, You Do Not Need to Hold Aspirin Before Thoracentesis

Aspirin should be continued and is not considered a contraindication for thoracentesis. 1

Primary Recommendation

The most recent and authoritative guideline (2025) from the Anaesthesia journal explicitly states that aspirin does not significantly increase bleeding risk and it is not necessary to discontinue aspirin before performing thoracentesis or pleural drainage 1. This recommendation is based on the classification of pleural puncture as a low-bleeding-risk procedure, where bleeding complications are infrequent, mild, and easily controlled.

Supporting Evidence Framework

Guideline Consensus

• Thoracentesis is classified as a low-bleeding-risk procedure where antiplatelet therapy—whether single or dual—is not considered a contraindication 1
• The 2022 American College of Chest Physicians guideline supports continuing antiplatelet drugs (including aspirin) for minor procedures, though it doesn't specifically address thoracentesis 2
• The critical distinction is that aspirin alone does not warrant procedure delay or discontinuation

Clinical Context

The bleeding risk from thoracentesis itself is remarkably low:

• Hemothorax occurs in less than 1% of cases 1
• Prospective observational data from 312 patients showed no hemothorax occurred in patients with bleeding risks (including anticoagulation and antiplatelet therapy) who underwent thoracentesis without medication correction 3

When Aspirin Might Need Consideration

While aspirin continuation is the standard approach, temporary discontinuation may be necessary in specific high-risk scenarios 1:

• Dual antiplatelet therapy (aspirin + P2Y12 inhibitor like clopidogrel) in combination with other hemostasis-modifying drugs
• Congenital or acquired coagulopathy in addition to aspirin use
• Multiple bleeding risk factors present simultaneously (e.g., aspirin + therapeutic anticoagulation + thrombocytopenia + uremia)

Important Caveat

Even in these complex scenarios, the decision is case-by-case and should weigh the urgency of the procedure against bleeding risk. The guideline emphasizes that most patients can safely proceed even with multiple risk factors 1.

Common Pitfalls to Avoid

1. Don't confuse aspirin with P2Y12 inhibitors: While aspirin is safe to continue, clopidogrel/ticagrelor may require interruption in certain contexts, particularly when combined with other risk factors 1

2. Don't delay urgent procedures: When thoracentesis is emergent, the procedure should not be postponed to discontinue aspirin 1

3. Don't routinely order pre-procedure hematocrit: Research shows no significant difference in pre- and post-procedural hematocrit levels in patients with bleeding risks versus those without 3

Practice Pattern Reality

Survey data reveals significant practice variation, with 96% of physicians willing to perform thoracentesis in patients on aspirin 4. This high acceptance rate aligns with current evidence-based recommendations, though the survey predates the 2025 guideline.

The bottom line: Continue aspirin, perform the thoracentesis with standard ultrasound guidance, and reserve medication adjustments only for patients with multiple compounding bleeding risk factors beyond aspirin alone.